{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:23:27Z","timestamp":1790821407737,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd002204.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000}}],"reference-count":43,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd002204.pub5","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T12:42:07Z","timestamp":1662122527000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis"],"prefix":"10.1002","volume":"2022","author":[{"given":"Natalie Z","family":"Francis","sequence":"additional","affiliation":[{"name":"Manchester Adult Cystic Fibrosis Centre; University of Manchester; Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin W","family":"Southern","sequence":"additional","affiliation":[{"name":"Department of Women's and Children's Health; University of Liverpool; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"key":"10.1002\/14651858.CD002204.pub5-BIB0001|cit1","first-page":"A2466","article-title":"Treatment of Aspergillus fumigatus in patients with cystic fibrosis: a randomized, controlled trial","volume":"185","author":"Aaron","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD002204.pub5-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"e36077","DOI":"10.1371\/journal.pone.0036077","article-title":"Treatment of Aspergillus fumigatus in patients with cystic fibrosis: a randomized, placebo-controlled pilot study","volume":"7","author":"Aaron","year":"2012","journal-title":"PLoS One"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD002204.pub5-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S1569-1993(08)60219-2","article-title":"Intravenous methylprednisolone pulse therapy vs. oral prednisone for allergic bronchopulmonary aspergillosis (ABPA) in CF","volume":"7","author":"Cohen-Cymberknoh","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Suppl","key":"10.1002\/14651858.CD002204.pub5-BIB0004|cit4","first-page":"A1184","article-title":"Intravenous monthly high-dose pulse methylprednisolone vs oral prednisone for therapy of allergic bronchopulmonary aspergillosis in cystic fibrosis","volume":"179\u00a0","author":"Cohen-Cymberknoh","year":"2009","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD002204.pub5-BIB0005|cit5","first-page":"S83","article-title":"Impact of early azole therapy on chronic colonisation with Aspergillus fumigatus during cystic fibrosis","volume":"56","author":"Gangneux","year":"2018","journal-title":"Medical Mycology"},{"key":"10.1002\/14651858.CD002204.pub5-BIB0006|cit6","unstructured":"An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab (Xolair) in cystic fibrosis complicated by allergic bronchopulmonary aspergillosis (ABPA) www.clinicaltrialsregister.eu\/ctr-search\/search?query=2007-006648-23"},{"key":"10.1002\/14651858.CD002204.pub5-BIB0007|cit7","unstructured":"An exploratory study to assess multiple doses of Omalizumab in patients with cystic fibrosis complicated by acute bronchopulmonary aspergillosis (ABPA) clinicaltrials.gov\/ct2\/show\/NCT00787917"},{"key":"10.1002\/14651858.CD002204.pub5-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"376287","DOI":"10.1155\/2010\/376287","article-title":"Use of nebulized amphotericin B in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis","volume":"2010","author":"Proesmans","year":"2010","journal-title":"International Journal of Pediatrics"},{"issue":"Suppl 32","key":"10.1002\/14651858.CD002204.pub5-BIB0009|cit9","first-page":"349, Abstract n","article-title":"Treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis: antifungal therapy with inhaled amphotericin B","volume":"44","author":"Proesmans","year":"2009","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD002204.pub5-BIB0010|cit10","unstructured":"Prospective validation and clinical evaluation of a new posaconazole dosing regimen for children and adolescents with cystic fibrosis and Aspergillus infection trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2019-004511-31-IT"},{"key":"10.1002\/14651858.CD002204.pub5-BIB0011|cit11","unstructured":"A new posaconazole dosing regimen for paediatric patients with cystic fibrosis and aspergillus infection clinicaltrials.gov\/show\/NCT04966234"},{"key":"10.1002\/14651858.CD002204.pub5-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"issue":"11","key":"10.1002\/14651858.CD002204.pub5-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/thx.44.11.925","article-title":"Corticosteroid treatment and prognosis in pulmonary eosinophilia","volume":"44","author":"Capewell","year":"1989","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD002204.pub5-BIB0014|cit14","unstructured":"Cystic Fibrosis Foundation 2020 Patient Registry Annual Data Report www.cff.org\/medical-professionals\/patient-registry\u00a0 2000"},{"key":"10.1002\/14651858.CD002204.pub5-BIB0015|cit15","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"3","key":"10.1002\/14651858.CD002204.pub5-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1378\/chest.100.3.813","article-title":"Adjunctive therapy of allergic bronchopulmonary aspergillosis with itraconazole","volume":"100","author":"Denning","year":"1991","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD002204.pub5-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0732-8893(92)90053-V","article-title":"In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents","volume":"15","author":"Denning","year":"1992","journal-title":"Diagnostic Microbiology and Infectious Disease"},{"issue":"12","key":"10.1002\/14651858.CD002204.pub5-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1038\/s41431-018-0234-z","article-title":"Estimating the age of p.(Phe508del) with family studies of geographically distinct European populations and the early spread of cystic fibrosis","volume":"26","author":"Farrell","year":"2018","journal-title":"European Journal of Human Genetics"},{"issue":"3","key":"10.1002\/14651858.CD002204.pub5-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1378\/chest.116.3.639","article-title":"Allergic bronchopulmonary aspergillosis in cystic fibrosis: reported prevalence, regional distribution, and patient characteristics","volume":"116","author":"Geller","year":"1999","journal-title":"Chest"},{"key":"10.1002\/14651858.CD002204.pub5-BIB0020|cit20","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"key":"10.1002\/14651858.CD002204.pub5-BIB0021|cit21","unstructured":"Higgins JP Eldridge S Li T Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"12","key":"10.1002\/14651858.CD002204.pub5-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S1286-4579(99)80518-8","article-title":"Pathogenicity of microbes associated with cystic fibrosis","volume":"1","author":"Hutchison","year":"1999","journal-title":"Microbes and Infection"},{"issue":"12","key":"10.1002\/14651858.CD002204.pub5-BIB0023|cit23","first-page":"851","article-title":"Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis","volume":"342","author":"Lai","year":"2000","journal-title":"The Lancet"},{"issue":"1 Pt 1","key":"10.1002\/14651858.CD002204.pub5-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/0091-6749(84)90482-2","article-title":"Allergic bronchopulmonary aspergillosis in cystic fibrosis","volume":"73","author":"Laufer","year":"1984","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"Suppl B","key":"10.1002\/14651858.CD002204.pub5-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/jac\/28.suppl_B.83","article-title":"Liposomal amphotericin B: safety data from a phase 2\/3 clinical trial","volume":"28","author":"Meunier","year":"1991","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"1","key":"10.1002\/14651858.CD002204.pub5-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1378\/chest.105.1.32","article-title":"Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis","volume":"105","author":"Mroueh","year":"1994","journal-title":"Chest"},{"issue":"2","key":"10.1002\/14651858.CD002204.pub5-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1378\/chest.115.2.364","article-title":"Allergic bronchopulmonary aspergillosis in cystic fibrosis: role of atopy and response to itraconazole","volume":"115","author":"Nepomuceno","year":"1999","journal-title":"Chest"},{"key":"10.1002\/14651858.CD002204.pub5-BIB0028|cit28","unstructured":"Page MJ Higgins JP Sterne JA Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 \u00a0Available from www.training.cochrane.org\/handbook"},{"issue":"12","key":"10.1002\/14651858.CD002204.pub5-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1136\/thx.50.12.1321","article-title":"Use of nebulised liposomal amphotericin B in the treatmenof Aspergillus fumigatus empyema","volume":"50","author":"Purcell","year":"1995","journal-title":"Thorax"},{"issue":"4","key":"10.1002\/14651858.CD002204.pub5-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/0002-9343(78)90579-X","article-title":"The assessment of immunologic and clinical changes occurring during corticosteroid therapy for allergic bronchopulmonary aspergillosis","volume":"64","author":"Rosenberg","year":"1978","journal-title":"American Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD002204.pub5-BIB0031|cit31","first-page":"450","article-title":"Five year follow-up of allergic bronchopulmonary aspergillosis","volume":"108","author":"Safirstein","year":"1973","journal-title":"American Review of Respiratory Disease"},{"key":"10.1002\/14651858.CD002204.pub5-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1478-4505-4-21","article-title":"\u00a0Improving the use of research evidence in guideline development: 9. Grading evidence and recommendations","volume":"4","author":"Sch\u00fcnemann","year":"2006","journal-title":"Health Research and Policy Systems"},{"key":"10.1002\/14651858.CD002204.pub5-BIB0033|cit33","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook\/archive\/v6.2"},{"issue":"5","key":"10.1002\/14651858.CD002204.pub5-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/adc.65.5.507","article-title":"Cystic fibrosis and allergic bronchopulmonary aspergillosis","volume":"65","author":"Simmonds","year":"1990","journal-title":"Archives of Disease in Childhood"},{"issue":"1","key":"10.1002\/14651858.CD002204.pub5-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1183\/09031936.02.00248002","article-title":"Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide","volume":"20","author":"Skov","year":"2002","journal-title":"European Respiratory Journal"},{"issue":"11","key":"10.1002\/14651858.CD002204.pub5-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJM200003163421102","article-title":"A randomised trial of itraconazole in allergic bronchopulmonary aspergillosis","volume":"342","author":"Stevens","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD002204.pub5-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0889-8561(05)70018-7","article-title":"Allergic bronchopulmonary aspergillosis: clinical perspectives","volume":"18","author":"Varkey","year":"1998","journal-title":"Immunology and allergy clinics of North America"},{"issue":"5","key":"10.1002\/14651858.CD002204.pub5-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1067\/mai.2003.1388","article-title":"Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomised controlled trial","volume":"111","author":"Wark","year":"2003","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"3","key":"10.1002\/14651858.CD002204.pub5-BIB0039|cit39","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001108.pub2","article-title":"Azoles for allergic bronchopulmonary aspergillosis","author":"Wark","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD002204.pub5-BIB0040|cit40","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002204","article-title":"Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis","author":"Elphick","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD002204.pub5-BIB0041|cit41","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002204.pub2","article-title":"Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis","author":"Elphick","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD002204.pub5-BIB0042|cit42","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002204.pub3","article-title":"Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis","author":"Elphick","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD002204.pub5-BIB0043|cit43","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002204.pub4","article-title":"Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis","author":"Elphick","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T14:49:04Z","timestamp":1697554144000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD002204.pub5"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":43,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002204.pub5","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,2]]}}}